OLIG2 is a marker of the fusion protein-driven neurodevelopmental transcriptional signature in alveolar rhabdomyosarcoma
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 91, 77-85
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- STRING v9.1: protein-protein interaction networks, with increased coverage and integrationNucleic Acids Research, 2012
- Fusion Gene-Negative Alveolar Rhabdomyosarcoma is Clinically and Molecularly Indistinguishable from Embryonal RhabdomyosarcomaJournal of Clinical Oncology, 2010
- Molecular Classification of Rhabdomyosarcoma—Genotypic and Phenotypic Determinants of DiagnosisThe American Journal of Pathology, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHROncogene, 2007
- Global gene expression profiling of PAX‐FKHR fusion‐positive alveolar and PAX‐FKHR fusion‐negative embryonal rhabdomyosarcomasThe Journal of Pathology, 2007
- Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar RhabdomyosarcomasCancer Research, 2006
- Rhabdomyosarcoma: Value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtypeCancer, 2004
- Myogenin is a Specific Marker for Rhabdomyosarcoma: An Immunohistochemical Study in Paraffin-Embedded TissuesLaboratory Investigation, 2000
- Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcomaNature Genetics, 1993